anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Uveal melanoma (UM) is the most common intraocular tumor in adults, and nearly 50% of patients develop metastatic disease with a high mortality rate. Therefore, the development of relevant preclinical in vivo models that accurately recapitulate the metastatic cascade is crucial. We exploited the chick embryo chorioallantoic membrane (CAM) xenograft model to quantify both experimental and spontaneous metastasis by qPCR analysis. Our study found that the transplanted UM cells spread predominantly and early in the liver, reflecting the primary site of metastasis in patients. Visible signs of pigmented metastasis were observed in the eyes, liver, and distal CAM. Lung metastases occurred rarely and brain metastases progressed more slowly. However, UM cell types of different origins and genetic profiles caused an individual spectrum of organ metastases. Metastasis to multiple organs, including the liver, was often associated with risk factors such as high proliferation rate, hyperpigmentation, and epithelioid cell type. The severity of liver metastasis was related to the hepatic metastatic origin and chromosome 8 abnormalities rather than monosomy 3 and BAP1 deficiency. The presented CAM xenograft model may prove useful to study the metastatic potential of patients or to test individualized therapeutic options for metastasis in different organs.
<P>PROBLEM TO BE SOLVED: To obtain a new compound that is useful as an antitachykinin agent.  <P>SOLUTION: The new compound is the novel piperidine derivative which has excellent tachykinin acceptor antagonistic action. Further, even in an in vivo test, the piperazine derivative shows strong suppressive action on the vasopermeability promotion reaction induced by tachykinin. Further, the piperazine derivative shows good migration and a long half life in blood when examined by a dynamic test after the compound is dosed to rats or guinea pigs and it has been found to be extremely stable in the blood of a variety of animals. Accordingly, the piperazine derivative is very useful as a new antitachykinin agent.  <P>COPYRIGHT: (C)2004,JPO
Adult patients scheduled to undergo cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy will be screened for eligibility. After induction of general anesthesia, ultrasound-guided bilateral transmuscular quadratus lomborum block will be done in QL block group. 0.375% ropivacaine will be injected to each side. Patients in control group will receive no block. Multimodal analgesia will be applied to every patient for postoperative pain control. Multimodal analgesic regimen included scheduled administration of acetaminophen, NSAIDs, and rescue opioids. Blinded investigator will assess pain scores at rest and on movement at 6, 12, 24, 48, 72 hours after surgery, analgesic consumptions, nausea, vomiting, and quality of recovery questionnaire.
Uremic Pruritus is still a common complication in end-stage renal disease patients. The pathogenesis of Uremic Pruritus is unknown, therefore treatments are ineffective. According to several studies Uremic Pruritus is not an isolated skin disease. It seems to be a systemic inflammatory disease with a deranged balance of T helper cell differentiation. In this study investigators considered to evaluate effect of Fumaria Parviflora L. in uremic pruritus by a double blind placebo control clinical trial. It is hypothesized that oral Fumaria Parviflora L. may minimize uremic pruritus by decreasing serum Interferon gamma (IFN-γ) and high-sensitive C reactive protein (hs-CRP).
Following OraVerse administration, phentolamine is 100% available from the submucosal injection site and peak concentrations are achieved 10-20 minutes after injection. Phentolamine systemic exposure increased linearly after 0.8 mg compared to 0.4 mg OraVerse intraoral submucosal injection. The terminal elimination half-life of phentolamine in the blood was approximately 2-3 hours.

Pediatrics

Following OraVerse administration, the phentolamine Cmax was higher (approximately 3.5-fold) in children who weighed between 15 and 30 kg (33 and 66 lbs) than in children who weighed more than 30 kg. However, phentolamine AUC was similar between the two groups. It is recommended that in children weighing 15-30 kg, the maximum dose of OraVerse should be limited to ½ cartridge (0.2 mg) (see Dosage and Administration section).

The pharmacokinetics of OraVerse in adults and in children who weighed more than 30 kg (66 lbs) are similar after intraoral submucosal injection.

OraVerse has not been studied in children under 3 years of age or weighing less than 15 kg (33 lbs). The pharmacokinetics of OraVerse after administration of more than 1 cartridge (0.4mg) has not been studied in children.
Despite several multicenter studies, there is no hard evidence on the superiority of a cyclosporine or tacrolimus based immunosuppressive regimen following kidney transplantation, in a single-center setting. Existing studies concentrated on benefits in safety and efficacy, but seldomly evaluated the cost-effectiveness of one treatment.

The study has been designed in a fashion as close to the daily clinical practice as possible. Patients are randomized in pairs, receiving kidneys from the same donor, thus avoiding donor-related bias. Those having specific indications or contraindications for one of the study medications were not entered into the study. All other study-related decisions are made only on a clinical basis and according to the standard practice of the center. Patients are followed on the intention-to-treat rule. Cost-effectiveness will be calculated on 12-month treatment for each patient entered into the study.
Autism spectrum disorders (ASDs) are described as generalized developmental disorders, with an average age of onset of 36 months. Genetic and environmental factors may contribute to this multifactorial disorder. The present study aimed to investigate the association of three GRIN2B polymorphisms, including rs1019385, rs1024893, and rs3764028, with ASDs. Based on the results, there was a significant difference regarding the genotype frequency of rs3764028 polymorphism between the control and case (ASD) groups (P = 0.027). According to the recessive model, this variant was associated with ASDs (P = 0.23). None of the eight haplotype models with frequencies above 0.5 showed significant differences between the case and control groups in terms of allelic frequency. The present results showed that the rs376028 variant was directly related to the phenotypic symptoms of ASDs.
Calcitonin gene-related peptide (CGRP) is synthesized and secreted by trigeminal ganglion neurons, and is a key neuropeptide involved in pain and immune regulation. This study investigates the expression of CGRP in the trigeminal ganglion (TG) and its regulatory role in the polarization of macrophages in rats with temporomandibular arthritis. A rat model of temporomandibular arthritis was established using CFA. Pain behavior was then observed. Temporomandibular joint (TMJ) and the TG were collected, and immunohistochemistry, immunofluorescence (IF) staining, and RT-qPCR were used to examine the expression of CGRP and macrophage-related factors. To investigate the impact of CGRP on macrophage polarization, both CGRP and its antagonist, CGRP 8-37, were separately administered directly within the TG. Statistical analysis revealed that within 24 h of inducing temporomandibular arthritis using CFA, there was a significant surge in CD86 positive macrophages within the ganglion. These macrophages peaked on the 7th day before beginning their decline. In this context, it's noteworthy that administering CGRP to the trigeminal ganglion can prompt these macrophages to adopt the M2 phenotype. Intriguingly, this study demonstrates that injecting the CGRP receptor antagonist (CGRP 8-37) to the ganglion counteracts this shift towards the M2 phenotype. Supporting these in vivo observations, we found that in vitro, CGRP indeed fosters the M2-type polarization of macrophages. CGRP can facilitate the conversion of macrophages into the M2 phenotype. The phenotypic alterations of macrophages within the TG could be instrumental in initiating and further driving the progression of TMJ disorders.
Human papillomavirus (HPV) drives cervical cancer (CaCx) pathogenesis and viral oncoproteins jeopardize global gene expression in such cancers. In this study, our aim was to identify differentially expressed coding (DEcGs) and long noncoding RNA genes (DElncGs) specifically sense intronic and Natural Antisense Transcripts as they are located in the genic regions and may have a direct influence on the expression pattern of their neighbouring coding genes. We compared HPV16-positive CaCx patients (N = 44) with HPV-negative normal individuals (N = 34) by employing strand-specific RNA-seq and determined the relationships between DEcGs and DElncGs and their clinical implications. By performing Gene set enrichment and protein-protein interaction (PPI) analyses of DEcGs, we identified enrichment of processes crucial for abortive virus life cycle and cancer progression. The DEcGs formed 16 gene clusters which we identified through Molecular Complex Detection (MCODE) plugin of Cytoscape. All the gene clusters portrayed cancer-related functions. We recorded significantly correlated expression levels of 79 DElncGs with DEcGs at proximal genomic loci based on Pearson's Correlation coefficients. Of these gene pairs, 24 pairs portrayed significantly altered correlation coefficients among patients, compared to normal individuals. Of these, 6 DEcGs of 6 such gene pairs, belonged to 5 of the identified gene clusters, one of which was survival-associated. Out of the 24 correlated DEcG: DElncG pairs, we identified 3 pairs, where expression of both members was significantly associated with patient overall survival. The findings justify the cooperative roles of these gene pairs, in patient prognostication, thereby bearing immense potential for translation. Thus, elucidation of correlative strengths between paired DElncGs and DEcGs in patient and normal samples, could serve as a foundation for identification of therapeutic and prognostic targets of HPV16-positive CaCx.
PURPOSE: A transdermal or scalp formulation containing transferosome with lyso-phospholipid and surfactant is provided to ensure excellent ALA skin permeability and high PpIX accumulation. CONSTITUTION: A transferosome composition contains 12% or more of lyso-phospholipid and surfactant. The lyso-phospholipid is lyso-phosphocholine. The surfactant is Tween20, Tween 60, Brij 72, Brij 76, or Brij 78. The side of the trasnferosome is 50-200 nm. A transdermal and scalp formulation contains the transferosome composition and a drug. The drug is 5-aminolevulinic acid, vitamin C, or a vitamin C derivative.
The invention provides an application of pirfenidone in a medicament for treating pancreatic diseases. The invention establishes a ranophanin-induced chronic pancreatitis mouse model. In vivo experiments find that pirfenidone significantly reduces pancreatic tissue acinar atrophy, inflammatory cell infiltration and tissue fibrosis. In vitro experiments prove that pirfenidone inhibits the activation and migration of pancreatic stellate cells and the synthesis of extracellular matrix, and promotes the apoptosis of the pancreatic stellate cells. The invention has the advantages that: the invention discovers that the pirfenidone has a protective effect on pancreatic fibrosis for the first time. The invention provides a new medical application of prescription drug pirfenidone and a new clinical treatment means for chronic pancreatitis.
Participants received 1 cycle of carboplatin area under the curve (AUC) 6 mg/mL/min with paclitaxel 200 mg/m\^2 and pembrolizumab 200 mg on Day 1. Approximately 3 weeks later, participants received carboplatin AUC 2 mg/mL/min with paclitaxel 45 mg/ m\^2 administered weekly for 6 weeks along with 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) in conjunction with standard thoracic radiotherapy (TRT) (60 Gray \[Gy\] in 2 Gy fractions administered 5 days per week for 6 weeks). Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
The invention relates to pepperphentonamine chloride jelly powder injection and a preparation method thereof; the preparation comprises 1 portion of pepperphentonamine chloride, 2.5-3.0 portions of excipient and 400-600 portions of water for injection with PH value of 1.5-5.5; the preparation is prepared through freezing drying. The excipient is mannitol, dextran, lactose, sugar, polyglycol, poloxamer and glycin, etc.; 1 portion of the pepperphentonamine chloride, 10 portions of the mannitol and 500 portions of the water for injection with PH value of 2.0-3.0 are preferably chosen. The pepperphentonamine chloride and the excipient are added into the water for injection to be heated (40-90 DEG C), ultrasonic oscillated, degermed, subpackaged, pre-frozen, multi-stage dried and packed to obtain the products. A brown glass bottle is preferably chosen for subpackage. The pepperphentonamine chloride preparation of the invention has excellent appearance, color and solubility, good stability and long preservation period. The invention also relates to application of the preparation used for preparing therapeutic drugs for heart failure and/or myocardial protection.
FIELD: medicine, otolaryngology. SUBSTANCE: at the background of medicinal therapy, tracheal intubation and physiotherapy it is necessary to make an impact upon affected parts of laryngeal mucosa behind the walls of intubation tube with air-gaseous flow containing 2000 - 2500 mg/cu. m nitrogen monoxide for 30-90 sec daily, at 3-8 seances/course. The present innovation decreases terms of intubation, prevents complications in the form of scar laryngeal and tracheal stenosis due to permeability of air-gaseous flow of nitrogen monoxide between the walls of intubation tube and mucosa and direct impact upon affected parts of mucosa that, in its turn, leads to stimulation of epithelization, improved circulation, decreased mucosal edema, activation of fibroblasts. EFFECT: higher efficiency in preventing infection of affected mucosa. 2 ex
The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
Unscheduled Bleeding and Spotting

Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different contraceptive product.

In a clinical trial of Blisovi 24 Fe, the frequency and duration of unscheduled bleeding and/or spotting was assessed in 743 women (3,823 28-day cycles). A total of 10 subjects (1.3%) discontinued Blisovi 24 Fe, at least in part, due to bleeding or spotting. Based on data from the clinical trial, [24 to 38%] of women using Blisovi 24 Fe experienced unscheduled bleeding per cycle in the six months of the trial. The percent of women who experienced unscheduled bleeding tended to decrease over time.

Amenorrhea and Oligomenorrhea

Women who use Blisovi 24 Fe may experience absence of withdrawal bleeding, even if they are not pregnant. In the clinical trial with Blisovi 24 Fe, 31 to 41% of the women using Blisovi 24 Fe did not have a withdrawal menses in at least one of 6 cycles of use. 

Some women may experience amenorrhea or oligomenorrhea after discontinuation of COCs, especially when such a condition was preexistent.

If scheduled (withdrawal) bleeding does not occur, consider the possibility of pregnancy. If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy.
More than 20 million Americans suffer from asthma, and nearly half of asthma sufferers do not have their asthma under control. Although commonly diagnosed using physiological measures of airflow and bronchial hyperreactivity, asthma pathophysiology is related to chronic inflammation of the airway.

Current diagnostic evaluation and monitoring are inadequate for proposed practice guidelines. The most commonly used test for evaluation of asthma is the measurement of airflow obstruction by spirometry. The National Asthma Education Prevention Program (NAEPP) and Expert Panel Reports set forth grading of asthma severity based on the frequency of symptoms, airflow, and the need for inhaled beta-agonists. Practice guidelines outline that the goals of therapy for asthma are to: maintain normal activity with near normal parameters of lung function, prevent exacerbations that lead to tissue injury, and avoid medication toxicity. In order to facilitate these goals, NAEPP defines key components for management including disease monitoring and stepped care pharmacotherapy. Unfortunately, there is no optimal plan for monitoring inflammation, which causes us to fail in key components in management of asthma. Limited options for anti-inflammatory treatments to control asthma likewise often lead to substantial morbidities due to treatment with high doses of corticosteroids. Our AIR program plans to develop novel asthma monitoring tests and design targeted therapeutics, which altogether may reduce toxicities and improve the long-term health of patients.

Impact on broad scientific advancement. Our cumulative studies provide fundamental information on the molecular mechanisms that contribute to unresolving and excessive inflammation that leads to tissue remodeling. This mechanistic knowledge is of broad scientific importance as nearly all chronic human diseases are defined by prolonged and active inflammation, with tissue destruction, and failed attempts at healing. Thus, our investigations will provide comprehensive knowledge and consequent translational deliverables that may be widely applicable as diagnostic strategies and therapies in other chronic inflammatory diseases.
PURPOSE:To provide an infusion containing an N-highly unsaturated- acyl-alpha-amino acid derivative. CONSTITUTION:The objective infusion contains an N-highly unsaturated- acyl-alpha-amino acid derivative which is a reaction product of a highly unsaturated fatty acid (e.g. gamma-linoleic acid, dihomo-gamma-linoleic acid, arachidonic acid, eicosapentaenoic acid or docosahexaenoic acid) with an alpha-amino acid. The alpha-amino acid is e.g. aspartic acid or glutamic acid and an oligopeptide having C-terminal can be used as the amino acid. The infusion can be prepared only by dispersing glycerol and an N-highly unsaturated-acyl-alpha-amino acid derivative in distilled water for injection without using intensive emulsifying agent or high-pressure emulsifier. If necessary, vitamins and minerals can be easily added to the infusion. Since the infusion can be supplied through mouth, vein or intestine, it can be utilized as an infusion for the improvement of nutrient balance or as a post-operative nutrient or remedy.
<P>PROBLEM TO BE SOLVED: To provide an osteoporosis preventive-therapeutic agent and an osteoclast differentiation inhibitor, both including an extract which is obtained by cultivating kudzu (Pueraria lobata) and stably extracting a functional component (isoflavones, etc.) from kudzu stem at a high production efficiency.  <P>SOLUTION: Both of the osteoporosis preventive-therapeutic agent and the osteoclast differentiation depressant include, as the effective component, a lignified current-year's living stem itself gathered in a large amount in kudzu cultivation and including a large amount of the functional component (isoflavones, etc.), or include the extract of the living stem. A drug medicine, a food and drink, etc., prepared by compounding the osteoporosis preventive-therapeutic agent or the osteoclast differentiation depressant, are also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Improved data ingestion techniques are provided. A data set comprising records is received, where each record contains one or more fields. A group of fields is identified, where each of the fields has a common metadata attribute. Metrics are determined for the group based on metadata associated with each field, and weight values are assigned to each of the metrics. A natural language processing (NLP) measure and a discreteness measure are generated for the group of fields based on the metrics and the weight values. A processing workflow is selected to use when ingesting data from the group of fields into a corpus, based on comparing the NLP measure and the discreteness measure to one or more predefined thresholds, and each of the fields in the group of fields are processed using the processing workflow.
Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
The mean apparent volume (Vβ) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, plasma concentrations as high as 10 mcg/mL will only occupy approximately 5% of the albumin binding sites. Thus, the unbound fraction for each enantiomer will be constant over the therapeutic range. A decrease in serum albumin, however, will result in increased free drug concentrations. Ketorolac tromethamine is excreted in human milk (see PRECAUTIONS – Nursing Mothers).
Certain steroid compounds which are 2. a. -cyano-4. a. , 5. a. -epoxy-3-oxo steroids notably trilostane, act on specific isoforms of the oestrogen receptor in human and animal cells. The compounds are used to treat certain conditions in hormone-sensitive organs such as but not exclusively breast, prostate, central nervous system, heart, blood vessels and uterus. The invention shows that trilostane and related compounds selectively modulate ligand binding to the oestrogen receptor and in particular to oestrogen receptor beta. Also claimed are particulate forms of these compounds which consist of particles having a mean equivalent sphere volume diameter of 12  m or less and 90% having a particle size less than 50  m.
Delirium, which generally is triggered by underlying medical conditions, is an acute and fluctuating disorder associated with attention and cognitive defects, and frequently accompanied by excessive arousal and perception-related problems. Delirium may lead to a variety of complications, e.g. cognitive impairments. Development of delirium is promoted by both anaesthesia and pain. Patients subjected to cardiac surgeries are at risk of delirium due to such factors as extracorporeal circulation applied during the intervention and various cardiovascular complications. Rapid identification of the problem may help eliminate avoidable complications which can be prevented at an early stage.